Tokyo, Japan, Dec 21, 2005 - (JCN) - Japanese biopharmaceutical company Sosei has announced that it and French pharmaceutical Laboratoire HRA Pharma (HRA) have entered into a sublicensing agreement with Sandoz/Hexal Australia, a wholly owned subsidiary of Novartis AG, for the distribution of SOH-075, an oral levonorgestrel emergency contraceptive developed by HRA.
Under the agreement terms, Sandoz Hexal will be licensed to distribute SOH-075 in Australia. Orally administered within 72 hours after an unprotected sexual intercourse, the drug can prevent pregnancy.
The agent is currently marketed in 60 countries worldwide, including France, Italy, South Korea and Taiwan, under the trade name of Norlevo.
In April 2001, Sosei has concluded a marketing agreement with HRA whereby Sosei can exclusively sell SOH-075 in Japan, Australia and New Zealand.
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2005 Japan Corporate News Network K.K.
COPYRIGHT 2005 Gale Group